Cited by 484Barrier Structure and Function StudiesDiabetes Treatment and ManagementRegulation of Appetite and Obesity

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier

Kastin, Abba J., Akerstrom, Victoria, Pan, Weihong·2002·Journal of Molecular Neuroscience

Open this paper in CoChat — free account

Abstract

Glucagon-like peptide-1 (GLP-1) reduces insulin requirement in diabetes mellitus and promotes satiety. GLP-1 in the periphery (outside the CNS) has been shown to act on the brain to reduce food ingestion. As GLP-1 is readily degraded in blood, we focused on the interactions of [Ser8]GLP-1, an analog with similar biological effects and greater stability, with the blood-brain barrier (BBB). The influx of radiolabeled [Ser8]GLP-1 into brain has several distinctive characteristics: 1. A rapid influx rate of 8.867 +/- 0.798 x 10(4) mL/g-min as measured by multiple-time regression analysis after iv injection in mice. 2. Lack of self-inhibition by excess doses of the unlabeled [Ser8]GLP-1 either iv or by in situ brain perfusion, indicating the absence of a saturable transport system at the BBB. 3. Lack of modulation by short-term fasting and some other ingestive peptides that may interact with GLP-1, including leptin, glucagon, insulin, neuropeptide Y, and melanin-concentrating hormone. 4. No inhibition of influx by the selective GLP-1 receptor antagonist exendin(9-39), suggesting that the GLP-1 receptor is not involved in the rapid entry into brain. Similarly, there was no efflux system for [Ser8]GLP-1 to exit the brain other than following the reabsorption of cerebrospinal fluid (CSF). The fast influx was not associated with high lipid solubility. Upon reaching the brain compartment, substantial amounts of [Ser8]GLP-1 entered the brain parenchyma, but a large proportion was loosely associated with the vasculature at the BBB. Finally, the influx rate of [Ser8]GLP-1 was compared with that of GLP-1 in a blood-free brain perfusion system; radiolabeled GLP-1 had a more rapid influx than its analog and neither peptide showed the self-inhibition indicative of a saturable transport system. Therefore, we conclude that [Ser8]GLP-1 and the endogenous peptide GLP-1 can gain access to the brain from the periphery by simple diffusion and thus contribute to the regulation of feeding.

Integrity signals

Registry

Crossref · 10.1385/jmn:18:1-2:07

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 518
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339
Distribution of glucagonlike peptide I (GLP‐I), glucagon, and glicentin in the rat brain: An immunocytochemical study
Jin, S.-L. C., Han, V. K. M., Simmons, J. G., Towle, A. C., Lauder, J. M., & Lund, P. K. (1988) · The Journal of Comparative Neurology · doi:10.1002/cne.902710405 · Cited by 332

Flagged first, then by citations

Show all 28 references

Sorted by citations

Items 301–400 of 484

Vagal Afferent Mediates the Anorectic Effect of Peripheral Secretin
Chu, J. Y. S., Cheng, C. Y. Y., Sekar, R., & Chow, B. K. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064859 · Cited by 28
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Yu, S., Wang, Y., Shen, H., Bae, E.-K., Li, Y., Sambamurti, K., Tones, M. A., Zaleska, M. M., Hoffer, B. J., & Greig, N. H. (2024) · GeroScience · doi:10.1007/s11357-024-01116-0 · Cited by 28
Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides
Lin, J., Yu, Z., & Gao, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c06851 · Cited by 28
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 28
At the Centennial of Michaelis and Menten, Competing Michaelis–Menten Steps Explain Effect of GLP ‐1 on Blood–Brain Transfer and Metabolism of Glucose
Gejl, M., Rungby, J., Brock, B., & GJEDDE, A. H. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 28
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 28
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 27
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 27
Glucagon‐related peptides and the regulation of food intake in chickens
Honda, K. (2016) · Animal Science Journal · doi:10.1111/asj.12619 · Cited by 27
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink‐Jensen, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70004 · Cited by 26
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 26
DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects
Zhang, G., Kim, S., Gu, X., Yu, S. P., & Wei, L. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00446-w · Cited by 26
Different mechanisms influencing permeation of PDGF‐AA and PDGF‐BB across the blood–brain barrier
Kastin, A. J., Akerstrom, V. L., Hackler, L., & Pan, W. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01933.x · Cited by 26
Self-citation
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer’s and Parkinson’s disease
Hölscher, C. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000087 · Cited by 25
SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 25
Metabolic factors in the regulation of hypothalamic innate immune responses in obesity
Folick, A., Cheang, R. T., Valdearcos, M., & Koliwad, S. K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00666-z · Cited by 26
Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
Colin, I. M., Szczepanski, L. W., Gérard, A.-C., & Elosegi, J. A. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.16 · Cited by 25
Estrogen and gut satiety hormones in vagus-hindbrain axis
Huang, K.-P., & Raybould, H. E. (2020) · Peptides · doi:10.1016/j.peptides.2020.170389 · Cited by 24
The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS
Keerie, A. F. A., Brown-Wright, H., Kirkland, I., Grierson, A. J., Alix, J. J. P., Hölscher, C., & Mead, R. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-96418-0 · Cited by 24
Myeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 25
GLP-1 in the Hypothalamic Paraventricular Nucleus Promotes Sympathetic Activation and Hypertension
Xu, X., Wang, J.-X., Chen, J.-L., Dai, M., Wang, Y., Chen, Q., Li, Y., Zhu, G., & Chen, A. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.2032-23.2024 · Cited by 23
Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes
Wang, Y., Wang, L., Shao, Y., Weng, S.-J., Yang, X., & Zhong, Y. (2023) · iScience · doi:10.1016/j.isci.2023.107680 · Cited by 23
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
HOFFMAN, S. S., & Adeli, K. (2024) · Medical Review · doi:10.1515/mr-2024-0011 · Cited by 23
Antidiabetic treatment, stroke severity and outcome
Magkou, D., & Τζιόμαλος, Κ. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.84 · Cited by 23
Current Perspectives on Long-term Obesity Pharmacotherapy
Wharton, S. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.07.005 · Cited by 22
Physiologic and Neural Controls of Eating
Moran, T. H., & Ladenheim, E. E. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.07.009 · Cited by 22
Low glucagon-like peptide-1 (GLP-1) concentration in serum is indicative of mild cognitive impairment in type 2 diabetes patients
Wu, P., Zhao, Y., Zhuang, X., Sun, A., Zhang, Y., & Ni, Y. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.08.012 · Cited by 22
Neuroendocrine Modulation of Food Intake and Eating Behavior
Iovino, M., Messana, T., Lisco, G., Mariano, F., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., & Triggiani, V. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220127114326 · Cited by 22
Bariatric surgery may reduce the risk of Alzheimer’s diseases through GLP-1 mediated neuroprotective effects
Keshava, H. B., Mowla, A., Heinberg, L. J., Schauer, P. R., Brethauer, S. A., & Aminian, A. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.05.002 · Cited by 22
Role of Exendin-4 in Brain Insulin Resistance, Mitochondrial Function, and Neurite Outgrowth in Neurons under Palmitic Acid-Induced Oxidative Stress
Jo, D., Yoon, G., & Song, J. (2021) · Antioxidants · doi:10.3390/antiox10010078 · Cited by 21
The Glucagon‐like peptide‐1 receptor agonist, exendin‐4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome
O’Brien, R., & O’Malley, D. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13738 · Cited by 21
Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats
Yu, Y.-W., Hsueh, S., Lai, J.-H., Chen, Y., Kang, S.-J., Chen, K., Hsieh, T.-H., Hoffer, B. J., Li, Y., Greig, N. H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041153 · Cited by 19
Expression of GLP-1 receptors in insulin-containing interneurons of rat cerebral cortex
Csajbók, É., Kocsis, Á. K., Faragó, N., Furdan, S., Kovács, B., Lovas, S., Molnár, G., Likó, I., Zvara, Á., Puskás, L. G., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4803-z · Cited by 19
Interaction of circulating GLP-1 and the response of the dorsolateral prefrontal cortex to food-cues predicts body weight development
Maurer, L., Mai, K., Krude, H., Haynes, J., Weygandt, M., & Spranger, J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.014 · Cited by 19
Suppression of BACE1 and amyloidogenic/RAGE axis by sitagliptin ameliorates PTZ kindling-induced cognitive deficits in rats
Safar, M. M., Shahin, N. N., Mohamed, A. F., & Abdelkader, N. F. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109144 · Cited by 19
Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
Lee, J. Y., Park, T., Hong, E., Amatya, R., Park, K., Park, Y.-H., Min, K. A., Jin, M., Lee, S., Hwang, S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120250 · Cited by 19
Central GLP-1 contributes to improved cognitive function and brain glucose uptake after duodenum-jejunum bypass on obese and diabetic rats
Ruze, R., Xu, Q., Liu, G., Li, Y., Chen, W., Cheng, Z., Xiong, Y., Liu, S., Zhang, G., Hu, S., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00126.2021 · Cited by 19
Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea
Kim, K. K. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.19.0013 · Cited by 18
Crosstalk between alcohol use disorder and obesity: two sides of the same coin?
Leggio, L., Farokhnia, M., Kenny, P. J., Pepino, M. Y., & Simmons, W. K. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03259-8 · Cited by 17
Acute but not chronic activation of brain glucagon‐like peptide‐1 receptors enhances glucose‐stimulated insulin secretion in mice
Tudurí, E., Beiroa, D., Porteiro, B., López, M., Diéguez, C., & Nogueiras, R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12488 · Cited by 17
Liraglutide Up-regulation Thioredoxin Attenuated Müller Cells Apoptosis in High Glucose by Regulating Oxidative Stress and Endoplasmic Reticulum Stress
Ren, X. S., Sun, L., Wei, L., Liu, J., Zhu, J., Yu, Q., Kong, H., & Kong, L. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1737137 · Cited by 17
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 18
PCSK2-null mice exhibit delayed intestinal motility, reduced refeeding response and altered plasma levels of several regulatory peptides
Gagnon, J., Mayne, J., Chen, A., Raymond, A., Woulfe, J., Mbikay, M., & Chrétien, M. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.11.010 · Cited by 17
Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Sutariya, B., Patel, M. S., Patel, H., Pandey, D., Patel, D. N., Bahekar, R. H., & Jain, M. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.068 · Cited by 17
Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile
Kalas, M. A., Dang, T. Q., Galura, G. M., Alvarado, L. A., Dwivedi, A. K., Deoker, A., & McCallum, R. W. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2022-002480 · Cited by 16
Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1
Liu, X., Zhang, N., Zhang, S., & Xu, P. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15502 · Cited by 16
Involvement of Intestinal Enteroendocrine Cells in Neurological and Psychiatric Disorders
Yu, L.-E., & Li, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10102577 · Cited by 16
Role of metabotropic glutamate receptors in the regulation of pancreatic functions
Babic, T., & Travagli, R. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.001 · Cited by 15
Evidence of metabolic memory-induced neurodegeneration and the therapeutic effects of glucagon-like peptide-1 receptor agonists via Forkhead box class O
Chen, S., Tang, Q., Wang, Y., Zheng, X., Chen, S., Sun, Y., Yao, W., & Gao, X. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.012 · Cited by 15
Involvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors
Keller, B. N., Hajnal, A. S., Browning, K. N., Arnold, A. C., & Silberman, Y. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.801825 · Cited by 16
Dietary Synergies in Appetite Control: Distal Gastrointestinal Tract
Woods, S. C. (2006) · Obesity · doi:10.1038/oby.2006.301 · Cited by 15
Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists
Feng, J., & Jin, T. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0026 · Cited by 14
Whey protein hydrolysates improve high-fat-diet-induced obesity by modulating the brain–peripheral axis of GLP-1 through inhibition of DPP-4 function in mice
Rai, C., & G., P. P. C. (2023) · European Journal of Nutrition · doi:10.1007/s00394-023-03162-4 · Cited by 14
Repurposing Licensed Drugs for Use Against Alzheimer’s Disease
Norins, L. C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210080 · Cited by 13
Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy
Zhou, Y., Li, Z., Cao, X., Ma, H., White, P. F., Xu, X., Jiang, Y., Sun, X.-J., & Cui, Y. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.007 · Cited by 13
Appetite-Related Gut Peptides in Obesity and Binge Eating Disorder
Geliebter, A., Ochner, C. N., & Aviram-Friedman, R. (2008) · American Journal of Lifestyle Medicine · doi:10.1177/1559827608317358 · Cited by 13
The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
Barilar, J. O., Perhoč, A. B., Knezović, A., Homolak, J., Virag, D., & Šalković‐Petrišić, M. (2023) · Biomedicines · doi:10.3390/biomedicines11041025 · Cited by 12
The protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 12
Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders
Li, Y., Vaughan, K. L., Wang, Y., Yu, S., Bae, E.-K., Tamargo, I. A., Kopp, K. O., Tweedie, D., Chiang, C., Schmidt, K. T., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01120-4 · Cited by 12
Systemic Co-Administration of Low-Dose Oxytocin and Glucagon-Like Peptide 1 Additively Decreases Food Intake and Body Weight
Maejima, Y., Yokota, S., Hidema, S., Nishimori, K., de Wet, H., & Shimomura, K. (2024) · Neuroendocrinology · doi:10.1159/000538792 · Cited by 12
Liraglutide improves cognition function in streptozotocin-induced diabetic rats by downregulating β-secretase and γ-secretase and alleviating oxidative stress in HT-22 cells
Ma, L., Liu, S.-F., Ma, Z.-Q., Guo, Y.-G., Li, M., Gao, Y., Wen, Y., Niu, Y., Sui, H.-X., Li, B.-S., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0723 · Cited by 12
Action of glucagon-like peptide 1 and glucose levels on corticotropin-releasing factor and vasopressin gene expression in rat hypothalamic 4B cells
Kageyama, K., Yamagata, S., Akimoto, K., Sugiyama, A., Murasawa, S., & Suda, T. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.023 · Cited by 12
Food and Fluid Intake
Moran, T. H., & Sakai, R. R. (2003) · Wiley eBooks · doi:10.1002/0471264385.wei0311 · Cited by 12
Exploring the Anxiolytic Potential of NPY by a Dipeptidyl Peptidase-IV Inhibitor in an Animal Model of PTSD
Dahan, M., Zohar, J., Todder, D., Mathé, A. A., & Cohen, H. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae062 · Cited by 11
GLP-1 agonists: a game changer in pain treatment and addiction
Bade, S., Hurdle, M. F. B., Bade, S., Encalada, S., Kanahan-Osman, S., & Gupta, S. (2025) · Pain Management · doi:10.1080/17581869.2025.2536998 · Cited by 11
RETRACTED: Long-Lasting Exendin-4-Loaded PLGA Nanoparticles Ameliorate Cerebral Ischemia/Reperfusion Damage in Diabetic Rats
Chung, C.-H., Chung, S., Cheng, Y., Yang, C., Jiang, P., Yang, C., & Chien, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030390 · Cited by 11
Retracted
The inactivation of extracellular signal-regulated kinase by glucagon-like peptide-1 contributes to neuroprotection against oxidative stress
Nakajima, S., Numakawa, T., Adachi, N., Yoon, H. S., Odaka, H., Ooshima, Y., & Kunugi, H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.052 · Cited by 11
Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death
Ahn, Y. J., Shin, H.-J., Jeong, E.-A., An, H. S., Lee, J.-Y., Jang, H., Kim, K., Lee, J., Shin, M. C., & Roh, G. S. (2021) · Cells · doi:10.3390/cells10102527 · Cited by 11
S 23521 Decreases Food Intake and Body Weight Gain in Diet‐Induced Obese Rats
Claret, M., Corominola, H., Canals, I., Nadal, B., Chavanieu, A., Pfeiffer, B., Renard, P., Gorostiaga, C., Delagrange, P., Grassy, G., et al. (2004) · Obesity Research · doi:10.1038/oby.2004.199 · Cited by 11
Are GLP ‐1 receptor agonists useful against traumatic brain injury?
Combs, C. K. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13224 · Cited by 11
Effects of obesity induced by high-calorie diet and its treatment with exenatide on muscarinic acetylcholine receptors in rat hippocampus
Silva, M. F. P., Alves, P. L., Alponti, R. F., Silveira, P. F., & Abdalla, F. M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113630 · Cited by 10
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
Hölscher, C. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.01.007 · Cited by 10
Reducing alcohol and/or cocaine-induced reward and toxicity via an epidermal stem cell-based gene delivery platform
Kong, Q., Li, Y., Yue, J., Wu, X., & Xu, M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01043-y · Cited by 10
The Role of Insulin and Incretins in Neuroinflammation and Neurodegeneration
(2015) · Immunoendocrinology · doi:10.14800/ie.391 · Cited by 10
Central GLP-1 Actions on Energy Metabolism
Velasquez, D., Beiroa, D., Vazquez, M. J., Romero, A., López, M., Diéguez, C., & Nogueiras, R. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00011-4 · Cited by 9
Detection of Impaired Cognitive Function in Rat with Hepatosteatosis Model and Improving Effect of GLP-1 Analogs (Exenatide) on Cognitive Function in Hepatosteatosis
Erbaş, O., Saraç, F., Aktuğ, H., & Peker, G. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/946265 · Cited by 9
Neuropathological links between T2DM and LOAD: systematic review and meta-analysis
Lemche, E., Hortobágyi, T., Kiecker, C. M., & Turkheimer, F. (2025) · Physiological Reviews · doi:10.1152/physrev.00040.2024 · Cited by 9
Incretin-Based Therapy for Type 2 Diabetes Mellitus
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 8
Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain
Kim, Y., & Song, J. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa080 · Cited by 8
Glucagon‐like peptide‐1 receptor differentially controls mossy cell activity across the dentate gyrus longitudinal axis
Steiner, A., Owen, B. M., Bauer, J. P., Seanez, L., Kwon, S., Biddinger, J. E., Huffman, R., Ayala, J. E., Nobis, W. P., & Lewis, A. S. (2022) · Hippocampus · doi:10.1002/hipo.23469 · Cited by 8
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 8
SANTORO S, VELHOTE MCP, MALZONI CE, MECHENAS ASG, DAMIANI D, MAKSOUD JG. Digestive Adaptation with Intestinal Reserve: A New Surgical Proposal for Morbid Obesity. Rev bras videocir 2004;2(3):130-138. Digestive Adaptation with Intestinal Reserve: A New Surgical Proposal for Morbid Obesity Adaptação Digestiva com Reserva Intestinal: Nova Proposta Cirúrgica para Obesidade Mórbida
Santoro, S., Carlos, M., Velhote, P., Malzoni, C. E., Mechenas, A. S. G., Damiani, D., & Maksoud, J. G. (2004) · Cited by 8
Glucagon-Like Peptide-1 and Diabetes
Monami, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/901954 · Cited by 8
Sweet taste receptors are the potential mediator involved in appetite regulation of grass carp in response to high digestible carbohydrates intake
Chen, H., Li, L., Wang, L.-H., Cheng, D.-H., Ma, H., Sun, M.-J., Yang, Y., & Yuan, X. (2022) · Aquaculture Reports · doi:10.1016/j.aqrep.2022.101386 · Cited by 7
Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology
Pal, B., & Chattopadhyay, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_117_23 · Cited by 7
DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease
Jeong, S. H., Kim, Y. J., Shin, J. Y., Oh, K. W., Lee, J. W., & Lee, P. H. (2025) · Gut · doi:10.1136/gutjnl-2025-334988 · Cited by 7
An Overview of Appetite Regulation Mechanisms
Şener, K., ALVER, E. N., & CEVHER, Ş. C. (2022) · Kocaeli Journal of Science and Engineering · doi:10.34088/kojose.1091078 · Cited by 7
Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review
Milonas, D., Didangelos, T., Hatzitolios, A. I., & Τζιόμαλος, Κ. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0580-z · Cited by 7
The Vagus Nerve and Ghrelin Function
Date, Y. (2014) · The Receptors · doi:10.1007/978-1-4939-0823-3_4 · Cited by 7
GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals
Larsson, M., Patrone, C., von Euler, M., Holst, J. J., & Nathanson, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0896-z · Cited by 7
Paying the Price for Eating Ice Cream: Is Excessive GLP-1 Signaling in the Brain the Culprit?
Berthoud, H. (2008) · Endocrinology · doi:10.1210/en.2008-0932 · Cited by 7
The Gut–Brain Axis and Peroxisome Proliferator-Activated Receptors in the Regulation of Epileptogenesis
Zubareva, O. E., & Melik-Kasumov, T. B. (2021) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093021040013 · Cited by 6
The clinical outcomes, appetite and metabolic effects of sleeve gastrectomy and Roux-en-Y gastric bypass: A comparative review
Dong, J., Jones, S., Tabbakh, Y., & Tan, T. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.100315 · Cited by 6
The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health
Hanna, A., Connelly, K. A., Josse, R. G., & McIntyre, R. S. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.972370 · Cited by 6
Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats
Łupina, M., Wąsik, A., Baranowska‐Bosiacka, I., Tarnowski, M., Słowik, T., Listos, P., Kotlinska, J. H., Kosik-Bogacka, D. I., Gutowska, I., & Listos, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053008 · Cited by 5
The GLP-1 analog, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice
Mermet, M., Denom, J., Mieczkowska, A., Wery, M., Biggs, E. K., Gribble, F. M., Reimann, F. M., Magnan, C., Cruciani‐Guglielmacci, C., & Mabilleau, G. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00086.2025 · Cited by 5
Impaired Glucose Metabolism in Alzheimer’s Disease and Diabetes
Mushtaq, G. (2014) · Enzyme Engineering · doi:10.4172/2329-6674.1000124 · Cited by 5
Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimer’s Disease
Morris, J. K., John, C. S., Green, Z. D., Wilkins, H., Wang, X., Kamat, A., Swerdlow, R. H., Vidoni, E. D., Petersen, M. E., O’Bryant, S. E., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.608862 · Cited by 5
An Update on Role of Bile Acids in Neurological Functions and Neurodegenerative Diseases: A Narrative Review
Kaur, K. K., Allahbadia, G., & Singh, M. (2023) · Journal of Clinical and Biomedical Investigation · doi:10.52916/jcbi234026 · Cited by 6
Gaps in our understanding of how vagal afferents to the small intestinal mucosa detect luminal stimuli
Fox, E. A., & Serlin, H. K. (2024) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00252.2023 · Cited by 5

Authors: Kastin, A. J., Akerstrom, V., & Pan, W.
Affiliations: Tulane University (US)
ORCID: Pan, Weihong
Venue: Journal of Molecular Neuroscience
Publisher: Springer Science and Business Media LLC
Published: 2002
Volume: 18
Issue: 1-2
Pages: 07-13
ISSN: 0895-8696 (ISSN-L)
DOI: 10.1385/jmn:18:1-2:07
OpenAlex: W2076140273
Cited by: 480
References: 28
Citations by year: 2026: 8 · 2025: 22 · 2024: 21 · 2023: 18 · 2022: 24 · 2021: 28 · 2020: 24 · 2019: 29 · 2018: 24 · 2017: 23 · 2016: 25 · 2015: 27 · 2014: 31 · 2013: 27 · 2012: 23
FWCI: 6.00
Type: journal article
Language: en
Open access: closed
Locations: Journal of Molecular Neuroscience (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Veterans Affairs
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases (DK-54880)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords: glucagon-like peptide-1, blood-brain barrier, brain uptake, passive diffusion, GLP-1 receptor, exendin-9-39, satiety, food intake regulation, cerebrospinal fluid reabsorption
MeSH terms: Animals, Appetite Regulation, Blood-Brain Barrier, Brain, Cerebrovascular Circulation, Dose-Response Relationship, Drug, Food Deprivation, Glucagon, Hypothalamic Hormones, Insulin, Male, Melanins, Mice, Inbred ICR, Neuropeptide Y, Peptide Fragments, Pituitary Hormones, Protein Precursors, Leptin, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks